Latest News
Slovenia ‘lights up’ during Blood Cancer Awareness Month
This September, our Slovenian member organisation, DruÅ¡tvo BKB, once again marked Blood Cancer Awareness Month and European Myeloma Day, with a wide range of activities dedicated to raising awareness and supporting patients across Slovenia. They…
Serbia marks European Myeloma Day with a packed September
Throughout September, the Multiple Myeloma Patient Association of Serbia (MMPAS) marked Blood Cancer Awareness Month with a powerful and heartfelt series of activities across the country — especially in smaller towns, where awareness of multiple…
Join our upcoming MPE and ASCERTAIN webinar on cost-effectiveness analysis
How are costs and medicine effectiveness part of decision-making in medicine access? Thursday, 9 October 2025, 17:00 – 18:30 CET Aimed at patients, carers and patient advocates, as well as to a general audience, the…
Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma care
Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side…
The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients
The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell…
- MO
- TU
- WE
- TH
- FR
- SA
- SU
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 1
- 2
- 3
- 4